- Home
- HUT vs KNSA Comparison
HUT vs KNSA Comparison
Compare HUT & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HUT
- KNSA
- Stock Information
- Founded
- HUT 2011
- KNSA 2015
- Country
- HUT United States
- KNSA United Kingdom
- Employees
- HUT N/A
- KNSA N/A
- Industry
- HUT Finance: Consumer Services
- KNSA Biotechnology: Pharmaceutical Preparations
- Sector
- HUT Finance
- KNSA Health Care
- Exchange
- HUT Nasdaq
- KNSA Nasdaq
- Market Cap
- HUT 1.6B
- KNSA 1.9B
- IPO Year
- HUT N/A
- KNSA 2018
- Fundamental
- Price
- HUT $16.70
- KNSA $28.44
- Analyst Decision
- HUT Strong Buy
- KNSA Strong Buy
- Analyst Count
- HUT 14
- KNSA 5
- Target Price
- HUT $26.64
- KNSA $38.80
- AVG Volume (30 Days)
- HUT 6.3M
- KNSA 707.0K
- Earning Date
- HUT 08-12-2025
- KNSA 07-22-2025
- Dividend Yield
- HUT N/A
- KNSA N/A
- EPS Growth
- HUT N/A
- KNSA N/A
- EPS
- HUT N/A
- KNSA N/A
- Revenue
- HUT $132,459,000.00
- KNSA $481,166,000.00
- Revenue This Year
- HUT $74.79
- KNSA $37.21
- Revenue Next Year
- HUT $116.78
- KNSA $5.32
- P/E Ratio
- HUT N/A
- KNSA N/A
- Revenue Growth
- HUT 0.24
- KNSA 59.45
- 52 Week Low
- HUT $8.73
- KNSA $17.38
- 52 Week High
- HUT $31.95
- KNSA $30.69
- Technical
- Relative Strength Index (RSI)
- HUT 50.50
- KNSA 55.24
- Support Level
- HUT $17.35
- KNSA $27.62
- Resistance Level
- HUT $18.60
- KNSA $28.69
- Average True Range (ATR)
- HUT 1.07
- KNSA 1.13
- MACD
- HUT -0.19
- KNSA -0.28
- Stochastic Oscillator
- HUT 39.39
- KNSA 45.78
About HUT Hut 8 Corp.
Hut 8 Corp is an energy infrastructure operator and Bitcoin miner with self-mining, hosting, managed services, and traditional data center operations across North America. The company has four reportable business segments: Power, Digital Infrastructure, Compute, and Other. It derives maximum revenue from the Compute segment which consists of Bitcoin Mining, GPU-as-a-Service, and Data Center Cloud operations. Its geographical segments include the United States and Canada, of which it generates the majority of revenue from the United States.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.